Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BTAI 
BioXcel Therapeutics Inc (BTAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BTAI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $19.4
1 Year Target Price $19.4
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -89.25% | Avg. Invested days 14 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 59.68M USD | Price to earnings Ratio - | 1Y Target Price 19.4 |
Price to earnings Ratio - | 1Y Target Price 19.4 | ||
Volume (30-day avg) 3 | Beta 0.06 | 52 Weeks Range 1.17 - 13.36 | Updated Date 08/28/2025 |
52 Weeks Range 1.17 - 13.36 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.9 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.13 | Actual -2.45 |
Profitability
Profit Margin - | Operating Margin (TTM) -13210% |
Management Effectiveness
Return on Assets (TTM) -68.72% | Return on Equity (TTM) -1766.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 149150702 | Price to Sales(TTM) 68.76 |
Enterprise Value 149150702 | Price to Sales(TTM) 68.76 | ||
Enterprise Value to Revenue 171.83 | Enterprise Value to EBITDA -0.75 | Shares Outstanding 14556700 | Shares Floating 14011593 |
Shares Outstanding 14556700 | Shares Floating 14011593 | ||
Percent Insiders 3.78 | Percent Institutions 6.19 |
Upturn AI SWOT
BioXcel Therapeutics Inc
Company Overview
History and Background
BioXcel Therapeutics, Inc. was founded in 2007. It's a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology.
Core Business Areas
- Neuroscience: Focuses on developing therapies for acute agitation, anxiety, and other neurological and psychiatric disorders.
- Immuno-oncology: Aims to develop novel therapies to enhance the bodyu2019s immune response to fight cancer.
Leadership and Structure
Dr. Vimal Mehta is the CEO. The company has a board of directors and various departments focusing on research, development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- Igalmi (sublingual dexmedetomidine): FDA-approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Market share data is still evolving as the drug is relatively new. Competitors include antipsychotics and benzodiazepines like lorazepam.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investments in research and development. Neuroscience and immuno-oncology are areas with high unmet needs and considerable growth potential.
Positioning
BioXcel is positioned as an innovative company leveraging AI to identify and develop novel therapies in neuroscience and immuno-oncology. Its competitive advantage lies in its AI platform and focus on specific unmet needs.
Total Addressable Market (TAM)
The TAM for acute agitation treatment is estimated to be substantial, potentially billions of dollars. BioXcel is targeting a significant portion of this market with Igalmi.
Upturn SWOT Analysis
Strengths
- AI-powered drug discovery platform
- FDA-approved product (Igalmi)
- Focus on unmet needs in neuroscience
- Experienced management team
Weaknesses
- Reliance on a single approved product
- High cash burn rate
- Need for further clinical trials for expanded indications
- Limited commercial infrastructure
Opportunities
- Expansion of Igalmi's label to include other indications
- Development of new drug candidates through its AI platform
- Strategic partnerships with larger pharmaceutical companies
- Potential for acquisitions
Threats
- Competition from established pharmaceutical companies
- Regulatory challenges and delays
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- JAZZ
- TEVA
- MYL
Competitive Landscape
BioXcel faces competition from companies with established products and larger market presence. Its AI platform provides a potential advantage in drug discovery, but it needs to successfully develop and commercialize its pipeline to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Data is not current, therefore I can not provide an accurate response.
Future Projections: Data is not current, therefore I can not provide an accurate response.
Recent Initiatives: Recent initiatives include expanding the commercial reach of Igalmi and advancing its pipeline of drug candidates.
Summary
BioXcel Therapeutics is an innovative biopharmaceutical company with an FDA-approved product and a promising AI-powered drug discovery platform. While Igalmi provides a revenue stream, the company's financial stability depends on expanding its product portfolio and managing its cash burn. The company faces competition from larger pharmaceutical players and must successfully navigate regulatory hurdles and clinical trial risks. Their innovative approach to drug development could lead to significant future growth if they succeed in bringing new products to market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioXcel Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-03-08 | Founder, CEO, President, & Director Dr. Vimal D. Mehta Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | |
Full time employees 37 | |||
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.